Bullish Outlook on Zura Bio Limited (ZURA) Amid Tibulizumab Phase 2 Clinical Trial Progress
The reaffirmed outlook came as Zura Bio Limited (NASDAQ:ZURA) reported its results for Q3 2025 on the same day.
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Suvretta Capital Management Aaron Cowen | 5,472,891 | $23,697,618 | +13% | 0.61% |
| 2. | Great Point Partners Jeffrey Jay And David Kroin | 3,815,930 | $16,522,977 | +21% | 6.81% |
| 3. | Adage Capital Management Phill Gross And Robert Atchinson | 3,045,444 | $13,186,773 | 0.02% | |
| 4. | Braidwell LP Alex Karnal | 2,472,806 | $10,707,250 | 0.32% | |
| 5. | Ikarian Capital Neil Shahrestani | 2,132,322 | $9,232,953 | 0.93% |
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $6.20 | 80,000 | $496,000.00 | 100,000 | 2024-05-17 | Filing | |
| $3.13 | 7,987 | $24,999.31 | 7,987 | 2024-04-22 | Filing | |
| $3.13 | 3,195 | $10,000.35 | 3,195 | 2024-04-22 | Filing | |
| $3.13 | 159,744 | $499,998.72 | 777,384 | 2024-04-22 | Filing | |
| $3.13 | 1,186,901 | $3,715,000.13 | 1,186,901 | 2024-04-22 | Filing |
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $2.73 | 1,001,633 | $2,734,458.09 | 0 | 2024-11-25 | Filing | |
| $2.70 | 3,800,000 | $10,260,000.00 | 1,001,633 | 2024-09-11 | Filing | |
| $3.87 | 51,728 | $200,187.36 | 2,085,418 | 2024-09-04 | Filing | |
| $4.00 | 2,000,000 | $8,000,000.00 | 4,801,633 | 2023-12-12 | Filing |
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 568,118 | $2,976,938 | 0% | |
| 2. | 470,540 | $2,465,629 | 0% | |
| 3. | 702 | $3,678 | 0% | |
| 4. | 100 | $524 | 0% | |
| 5. | 142 | $1 | 0% |